Restoring a Licence Requires a Credible Performance Relationship

CASI Pharmaceuticals and Acrotech Biopharma: exclusive licensing, performance and commercial reset.

Reference: USG-ACA-INS-1008-V1.0-EN
Edition: English Version 1.0 · 2026
Language: English
Publisher: USG Academy
Responsible team: USG Academy
Series: Insight

About this publication

An analysis of how performance expectations, supply, market conditions and delivery capacity must reconnect if an exclusive licence is to continue sustainably.

In this publication

Case context
Licence performance
Commercial reset
Continuation plan

Published editions retain their reference, version and language record. Revisions are identified as new editions.